Pyrazolo[4,3-c][1,2]benzothiazines 5,5-Dioxide: A Promising New Class of Staphylococcus aureus NorA Efflux Pump Inhibitors
Journal of Medicinal Chemistry2012Vol. 55(7), pp. 3568–3572
Citations Over TimeTop 10% of 2012 papers
Stefano Sabatini, Francesca Gosetto, Serena Serritella, Giuseppe Manfroni, Oriana Tabarrini, Nunzio Iraci, Jean Pierre Brincat, Emanuele Carosati, Milena Villarini, Glenn W. Kaatz, Violetta Cecchetti
Abstract
The increasing resistance to antibacterials commonly employed in the clinic and the growth of multidrug resistant strains suggest that the development of new therapeutic approaches should be of primary concern. In this context, EPIs may restore life to old drugs. In the present work, the EPI activity of the COX-2 inhibitor celecoxib was confirmed and a new class of pyrazolo[4,3-c][1,2]benzothiazine 5,5-dioxide analogues acting as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump was identified.
Related Papers
- → The role of RND-type efflux pumps in multidrug-resistant mutants of Klebsiella pneumoniae(2020)77 cited
- → Antimicrobial Resistance: Two-Component Regulatory Systems and Multidrug Efflux Pumps(2023)71 cited
- → Do proton‐pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?(2007)46 cited
- → Celecoxib and Heterotopic Bone Formation After Total Hip Arthroplasty(2013)45 cited
- Progress on Escherichia coli AcrAB-TolC Multidrug Efflux Pump and Its Regulation(2008)